The global non-insulin therapies for diabetes market is slated to grow on an exponential note with a sizable increase in incidence of type 2 diabetes followed by governments and non-government agencies collaborating to devise better measures to cure it, with non-insulin therapies being the epicenter.
The companies operating in the non-insulin therapies for diabetes market are reaching out to the untapped geographies in order to apprise them of the advantages of non-insulin therapies for diabetes, especially in the low-income countries where affordable medications for diabetes are recommended.
Various cases of type 2 diabetes go undiagnosed in these countries. The kay players are also devising means to create awareness on this count.
Non-insulin therapies are generally preferred by healthcare personnel in patients suffering from type 2 diabetes, in which body either fails to produce enough insulin or is incapable of using the insulin that it produces.
Certain non-insulin agents facilitate increase of insulin release from the pancreatic cells (sulfonylureas), whereas some of them increase glucose uptake peripherally and reduce hepatic glucose output (Biguanides).
There are agents slowing down digestion of starch in the small intestine (alpha glucosidase inhibitors). Certain medications facilitate reduction of post-meal sugar by blocking some enzymes (Incretin mimetics).
The last decade has seen a drastic rise in launching and approvals of non-insulin therapies for diabetes. Various drugs under the category of SGL2 inhibitors such as Empagliflozin, Canagliflozin, and Dapagliflozin were launched after the year 2013.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Diabetes is a metabolic, chronic disease that is characterized by elevation in the levels of blood glucose (also called blood sugar), which, over the period of time, results in serious damage to heart, kidneys, blood vessels, eyes, and nerves.
Type 2 diabetes occurs in adults when body turns out to be resistant to insulin or does not produce insulin sufficient for the body. In other words, type 2 diabetes happens due to improper regulation of body sugar as fuel.
As per the WHO, 422 million people worldwide are living with diabetes, with 1.5 million succumbing to it.
Need to combat type 2 diabetes through non-insulin therapies is thus driving the non-insulin therapies for diabetes market.
Non-insulin-based drugs for diabetes work toward the direction of lessening blood glucose level and keeping up for ideal glycemic control. For instance, certain operators increment insulin discharge from the pancreatic cells (Sulfonylureas), certain specialists increment the glucose take-up and decrease yield of hepatic glucose (Biguanides).
Some operators curtail assimilation of starch in the small digestive tract (alpha glucosidase inhibitors), and some prescriptions diminish post-supper sugar by obstruction of some chemicals.
The WHO states that diabetes is amongst the top 3 causes of fatalities amongst the noncommunicable diseases across the globe. The governments are collaborating with various research institutes, hospitals, and non-government agencies to create awareness regarding type 2 diabetes and curative measures regarding the same.
They are also providing subsidies in order to conduct research on this count. For instance, the Department of Health & Family Welfare, Government of India, provides financial and technical support to states/union territories under the National Programme for Prevention and Control of non-communicable diseases including diabetes.
Continual helps rendered as mentioned above is thus expanding the non-insulin therapies for diabetes market size.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest non-insulin therapies for diabetes market insights, North America dominated the non-insulin injection landscape in 2023 and the scenario is expected to persist during the forecast period. This is attributed to rise in incidence of type 2 diabetes in the U.S. followed by sizable spending on healthcare.
As per the Centers for Disease Control and Prevention, over 38 million Americans suffer from diabetes, with around 90-95% contracting type 2 diabetes.
Asia Pacific’s non-insulin therapies for diabetes market growth is ascribed to growing awareness about the importance of non-insulin treatments for type 2 diabetes. As per the National Institutes of Health, 23-30% of the youth over here suffers from type 2 diabetes and the percentage is expected to rise during the forecast period.
The key participants in the non-insulin therapies for diabetes market are conducting clinical trials regarding devising non-insulin therapies for diabetes followed by approvals from the regulatory authorities.
GSK plc, Eli Lilly and Company, Sumitomo Pharma, Intarcia Therapeutics, Servier Laboratories, Pfizer Inc., Merck & Co., Inc., Dong-A Pharmaceutical Co., Ltd., Luye Pharma Group, and Eurofarma Laboratories SA are some of the key players covered in the non-insulin therapies for diabetes market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 31.8 Bn |
| Market Forecast (Value) in 2034 | US$ 58.6 Bn |
| Growth Rate (CAGR) | 5.8% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 31.8 Bn in 2023
It is projected to grow at a CAGR of 5.8% from 2024 to 2034
Growing incidence of type 2 diabetes and rise in collaboration between the key players and government/non-government agencies
Hospital pharmacy segment accounted for the largest share in 2023
North America was the dominant region in 2023
GSK plc, Eli Lilly and Company, Sumitomo Pharma, Intarcia Therapeutics, Servier Laboratories, Pfizer Inc., Merck & Co., Inc., Dong-A Pharmaceutical Co., Ltd., Luye Pharma Group, and Eurofarma Laboratories SA
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Non-insulin Therapies for Diabetes Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Non-insulin Therapies for Diabetes Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Biguanides
6.3.2. Sulfonylureas
6.3.3. Thiazolidinediones
6.3.4. Alpha-Glucosidase Inhibitors
6.3.5. DPP-4 Inhibitors
6.3.6. GLP-1 Analogs
6.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2020-2034
7.3.1. Oral
7.3.2. Intramuscular
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Non-insulin Therapies for Diabetes Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2020-2034
10.3.1. Biguanides
10.3.2. Sulfonylureas
10.3.3. Thiazolidinediones
10.3.4. Alpha-Glucosidase Inhibitors
10.3.5. DPP-4 Inhibitors
10.3.6. GLP-1 Analogs
10.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
10.4. Market Value Forecast, by Route of Administration, 2020-2034
10.4.1. Oral
10.4.2. Intramuscular
10.5. Market Value Forecast, by Distribution Channel, 2020-2034
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Route of Administration
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Non-insulin Therapies for Diabetes Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2020-2034
11.3.1. Biguanides
11.3.2. Sulfonylureas
11.3.3. Thiazolidinediones
11.3.4. Alpha-Glucosidase Inhibitors
11.3.5. DPP-4 Inhibitors
11.3.6. GLP-1 Analogs
11.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
11.4. Market Value Forecast, by Route of Administration, 2020-2034
11.4.1. Oral
11.4.2. Intramuscular
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Non-insulin Therapies for Diabetes Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2020-2034
12.3.1. Biguanides
12.3.2. Sulfonylureas
12.3.3. Thiazolidinediones
12.3.4. Alpha-Glucosidase Inhibitors
12.3.5. DPP-4 Inhibitors
12.3.6. GLP-1 Analogs
12.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
12.4. Market Value Forecast, by Route of Administration, 2020-2034
12.4.1. Oral
12.4.2. Intramuscular
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospital Pharmacy
12.5.2. Retail Pharmacy
12.5.3. Online Pharmacy
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Route of Administration
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Non-insulin Therapies for Diabetes Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2020-2034
13.3.1. Biguanides
13.3.2. Sulfonylureas
13.3.3. Thiazolidinediones
13.3.4. Alpha-Glucosidase Inhibitors
13.3.5. DPP-4 Inhibitors
13.3.6. GLP-1 Analogs
13.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
13.4. Market Value Forecast, by Route of Administration, 2020-2034
13.4.1. Oral
13.4.2. Intramuscular
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospital Pharmacy
13.5.2. Retail Pharmacy
13.5.3. Online Pharmacy
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Route of Administration
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Non-insulin Therapies for Diabetes Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2020-2034
14.3.1. Biguanides
14.3.2. Sulfonylureas
14.3.3. Thiazolidinediones
14.3.4. Alpha-Glucosidase Inhibitors
14.3.5. DPP-4 Inhibitors
14.3.6. GLP-1 Analogs
14.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
14.4. Market Value Forecast, by Route of Administration, 2020-2034
14.4.1. Oral
14.4.2. Intramuscular
14.5. Market Value Forecast, by Distribution Channel, 2020-2034
14.5.1. Hospital Pharmacy
14.5.2. Retail Pharmacy
14.5.3. Online Pharmacy
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Route of Administration
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. GSK plc
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Eli Lilly and Company
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sumitomo Pharma
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Intarcia Therapeutics
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Servier Laboratories
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Pfizer Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Merck & Co., Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Dong-A Pharmaceutical Co., Ltd.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Luye Pharma Group
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Eurofarma Laboratories SA
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 02: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 03: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 04: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 07: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 08: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 09: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 11: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 12: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 13: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 15: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 16: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 17: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 19: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 20: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 21: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 23: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 24: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Drug Class, 2023
Figure 03: Global Non-insulin Therapies for Diabetes Market Value Share, by Drug Class, 2023
Figure 04: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Route of Administration, 2023
Figure 05: Global Non-insulin Therapies for Diabetes Market Value Share, by Route of Administration, 2023
Figure 06: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 07: Global Non-insulin Therapies for Diabetes Market Value Share, by Distribution Channel, 2023
Figure 08: Global Non-insulin Therapies for Diabetes Market Value Share, by Region, 2023
Figure 09: Global Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 11: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 13: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 14: Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 15: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 16: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 22: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 23: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 24: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 26:North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 27: Europe Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 31: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 32: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 33: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 35: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 36: Asia Pacific Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 40: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 41: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 42: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 44: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 45: Latin America Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 49: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 50: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 51: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 53: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 54: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 58: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 59: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 60: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 62: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Non-insulin Therapies for Diabetes Market
